Genetic predisposition to statin myopathy

Purpose of reviewGenetic predisposition to statin myopathy is a rapidly expanding area of investigation. This review summarizes the latest information on genetic risk factors associated with statin-induced myopathy. Genetic determinants involved in both pharmacokinetics of statins and metabolic muscle diseases are discussed. Data are provided on the prevalence of statin use in the United States; incidence of associated myopathy; terminology relating to statin myopathy and genetic susceptibility; and common myths surrounding this disorder. Recent findingsTechnological advances now make it possible to identify genetic variation in the human genome that reveals disease-causing mutations and single nucleotide polymorphisms associated with disease. More than 30 000 individuals in the United States suffer from severe life-threatening symptoms of statin-induced myopathy that may, in some cases, persist long after the cessation of therapy. Genes of interest include those involved in the pharmacokinetics of the statin response, muscle atrophy, exercise intolerance, pain perception, and mitochondrial energy metabolism. SummaryGenetic analysis for variants and disease-causing mutations relevant to statin myopathy will provide predisposition testing for this and other drug-induced disorders. This testing will become an integral part of personalized medicine that will contribute to the safe and informed use of selected drugs and improved compliance.

[1]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[2]  V. Pertegato,et al.  Functional characterization of human COQ4, a gene required for Coenzyme Q10 biosynthesis. , 2008, Biochemical and biophysical research communications.

[3]  W. Feeman.  Statin-fibrate combination therapy. , 2008, The American journal of cardiology.

[4]  M. Yamagishi,et al.  Comparison of Effects of Pitavastatin and Atorvastatin on Plasma Coenzyme Q10 in Heterozygous Familial Hypercholesterolemia: Results From a Crossover Study , 2008, Clinical pharmacology and therapeutics.

[5]  Dan M Roden,et al.  Genetic determinants of response to warfarin during initial anticoagulation. , 2008, The New England journal of medicine.

[6]  E. Nabel,et al.  Pharmacogenomics--ready for prime time? , 2008, The New England journal of medicine.

[7]  N. Drouot,et al.  ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. , 2008, American journal of human genetics.

[8]  S. Baker,et al.  A Neuromuscular Approach to Statin-Related Myotoxicity , 2008, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[9]  Michiaki Yamashita,et al.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. , 2007, The Journal of clinical investigation.

[10]  M. Hirata,et al.  The genetic determinants of atorvastatin response. , 2007, Current opinion in molecular therapeutics.

[11]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[12]  Russell A. Wilke,et al.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges , 2007, Nature Reviews Drug Discovery.

[13]  M. Lapeyre-Mestre,et al.  Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study , 2007, Annals of the rheumatic diseases.

[14]  T. Frudakis,et al.  CYP2D6*4 polymorphism is associated with statin-induced muscle effects , 2007, Pharmacogenetics and genomics.

[15]  A. Windemuth,et al.  Physiogenomic association of statin‐related myalgia to serotonin receptors , 2007, Muscle & nerve.

[16]  Bruce Carleton,et al.  Genotypic Approaches to Therapy in Children , 2007, Annals of the New York Academy of Sciences.

[17]  S. Dimauro,et al.  The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. , 2007, Brain : a journal of neurology.

[18]  T. A. Jacobson,et al.  The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis , 2007, Current opinion in lipidology.

[19]  R. Krauss,et al.  Pharmacogenomics of statin response , 2007, Current opinion in lipidology.

[20]  P. Thompson,et al.  The role of coenzyme Q10 in statin-associated myopathy: a systematic review. , 2007, Journal of the American College of Cardiology.

[21]  M. McNurlan,et al.  Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. , 2007, The American journal of cardiology.

[22]  G. Schmitz,et al.  Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy , 2007, Current opinion in lipidology.

[23]  A. Munnich,et al.  Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. , 2007, The Journal of clinical investigation.

[24]  S. Dimauro,et al.  Mutations in coenzyme Q10 biosynthetic genes. , 2007, The Journal of clinical investigation.

[25]  Georgirene Vladutiu.  Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al. , 2007, Arthritis and rheumatism.

[26]  F. Mastaglia,et al.  Progressive myopathy with up-regulation of MHC-I associated with statin therapy , 2007, Neuromuscular Disorders.

[27]  T. Moustafa,et al.  Primary sclerosing cholangitis – The arteriosclerosis of the bile duct? , 2007, Lipids in Health and Disease.

[28]  R. Wortmann,et al.  Myotoxicity associated with lipid-lowering drugs , 2007, Current opinion in rheumatology.

[29]  S. Dimauro,et al.  Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. , 2006, American journal of human genetics.

[30]  G. Fonarow,et al.  Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. , 2006, American heart journal.

[31]  Lisa Christopher-Stine,et al.  Statin myopathy: an update , 2006, Current opinion in rheumatology.

[32]  P. Neuvonen,et al.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin , 2006, Clinical pharmacology and therapeutics.

[33]  H. Hoppeler,et al.  Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia , 2006, The Journal of pathology.

[34]  D. Figarella-Branger,et al.  In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. , 2006, Arthritis and rheumatism.

[35]  Zachary Simmons,et al.  Genetic risk factors associated with lipid‐lowering drug‐induced myopathies , 2006, Muscle & nerve.

[36]  G. Comi,et al.  Familial idiopathic hyper‐CK‐emia: An underrecognized condition , 2006, Muscle & nerve.

[37]  J. Mckenney,et al.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. , 2006, The American journal of cardiology.

[38]  Alicja R Rudnicka,et al.  Statin safety: a systematic review. , 2006, The American journal of cardiology.

[39]  P. Thompson,et al.  An assessment of statin safety by muscle experts. , 2006, The American journal of cardiology.

[40]  H. Bays.  Statin safety: an overview and assessment of the data--2005. , 2006, The American journal of cardiology.

[41]  H. Bays,et al.  Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. , 2006, The American journal of cardiology.

[42]  M. Fromm,et al.  Pharmacogenomics of human OATP transporters , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[43]  R. Kollek,et al.  Pharmacogenetics, Adverse Drug Reactions and Public Health , 2006, Public Health Genomics.

[44]  S. Dimauro,et al.  A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. , 2006, American journal of human genetics.

[45]  A. Windemuth,et al.  Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. , 2005, Pharmacogenomics.

[46]  R. Hui,et al.  Differential Association Between Statin Exposure and Elevated Levels of Creatine Kinase , 2005, The Annals of pharmacotherapy.

[47]  Richard Platt,et al.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.

[48]  J. England,et al.  Statin-Associated Myopathy with Normal Creatine Kinase Levels , 2002, Annals of Internal Medicine.

[49]  S. Grundy,et al.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. , 2002, Circulation.

[50]  S. Sugano,et al.  Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene , 2001, Nature Genetics.

[51]  R. Haller.  Treatment of McArdle disease. , 2000, Archives of neurology.

[52]  B. Gersh.  Effect of Coenzyme Q10 on Myopathic Symptoms in Patients Treated With Statins , 2008 .

[53]  P. Thompson,et al.  The Role of Coenzyme Q 10 in Statin-Associated Myopathy , 2007 .

[54]  B. Miskie,et al.  Lipids in Health and Disease , 2007 .